Key Drivers
- Margin Strength
- Debt Leverage
- Cash Generation
AIAI Summary
LLY is no longer just a high-growth drug story but a scale-and-execution bet: investors should focus on whether Lilly can convert Mounjaro/Zepbound demand into a durable multi-product platform before pricing pressure, Novo competition, and a demanding valuation compress returns.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Debt Leverage
- •Cash Generation
LLY combines exceptional profitability and cash generation with meaningful leverage and a demanding valuation, leaving the stock fundamentally strong but price-sensitive.
Price Behavior
Key Price Behavior Insights:
- •Sharp rebound
- •Support rebuilt
- •Resistance capped
Over the last month, LLY rebounded sharply from about $850 and is holding near $1,005, but it remains stuck below $1,010-$1,015 resistance, so a clean break above $1,015 is needed to confirm the move.
Sharp rebound from about $850 on 2026-04-29 after the late-April selloff
Sentiment & News
Key News Insights:
- •Earnings beat
- •Obesity growth
- •Capacity expansion
Eli Lilly rallied on a strong Q1 earnings beat and raised 2026 outlook driven by Mounjaro/Zepbound sales, while major pipeline and manufacturing investments and rising Novo Nordisk competition kept the growth story strong but increasingly contested.
The news is net positive for Lilly, supporting momentum and long-term growth expectations despite intensifying competition
Similar Companies in Healthcare
Other companies in the same sector with AI ratings